The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
Engineering precision nanoparticles for drug delivery
Open accessAbstract
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers - systemic, microenvironmental and cellular - that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The literature has shown that nanoparticles with a diameter greater than 200 nm pose a risk of activating the complement system. Particles with diameters of 50 and 200 nm can escape from the splenic space, enter the sinusoidal endothelial pores, and accumulate in large quantities at sites of liver fibrosis (29, 30).”
From Matrix mechanical remodeled carrier-free nanosystem for programmable closed-loop reversal of liver fibrosis via STING alkylation (2025) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To avoid these limitations, non‐positively charged vectors were also developed by conjugating nucleic acids into nanoparticles, which however requires complicated synthesis procedure, and the transfection efficiency is strongly affected by the size, shape, and surface environment of the nanoparticles.[ 16 ]”
From A General and Efficient Strategy for Gene Delivery Based on Tea Polyphenols Intercalation and Self‐Polymerization (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To avoid these limitations, non‐positively charged vectors were also developed by conjugating nucleic acids into nanoparticles, which however requires complicated synthesis procedure, and the transfection efficiency is strongly affected by the size, shape, and surface environment of the nanoparticles.[ 16 ]”
From A General and Efficient Strategy for Gene Delivery Based on Tea Polyphenols Intercalation and Self‐Polymerization (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“After modification or stimulation by corresponding factors, these smart nanoparticles efficiently aggregate at the target location and release their payloads, establishing a smart treatment mode.8–12”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [9]
In the citing paper
“Nanoparticles taken intravenously can circulate for extended period of time with reduced clearance rates from the renal system due to their ultra-small size and superior drug loading and encapsulation efficacy.11”
From Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Nishita, M., Park, S.-Y., Nishio, T., Kamizaki, K., Wang, Z., Tamada, K., Takumi, T., Hashimoto, R., Otani, H., Pazour, G. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-016-0028-x · Cited by 15,947
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Institutional Repository of Leibniz Universität Hannover (Leibniz Universität Hannover) · doi:10.15488/5174 · Cited by 8,378
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07882-8 · Cited by 8,162
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodríguez-Torres, M. D. P., Acosta‐Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 7,085
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Research works printed but not linked: 2
- Pieter, S. & Mahmoudi, M. Drug Delivery Systems (World Scientific, 2017).
- Chacón-Lozsán, F., et al. Hemodynamic management of high blood pressure. Ther. Adv. Cardiol. 1, 73–79 (2017).
Cited by
Sorted by citations
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Metadata
- Authors
- Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R.
- Affiliations
- Abramson Cancer Center (US)
- University of Pennsylvania (US)
- The University of Texas at Austin (US)
- Corresponding author
- Mitchell, Michael J.
- Peppas, Nicholas A.
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2020-12-04
- Volume
- 20
- Issue
- 2
- Pages
- 101-124
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC7717100
- OpenAlex
- W3109746568
- Cited by
- 7,933
- References
- 316
- Citations by year
- 2026: 1402 · 2025: 1818 · 2024: 1723 · 2023: 1460 · 2022: 1082 · 2021: 441 · 2020: 2
- FWCI
- 49.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation (DGE-184529 8, 1845298, 1033746)
- American Association for Cancer Research (18-80-44-MITC, 18-80-44)
- American Cancer Society (129784‐IRG‐16‐188‐38‐IRG)
- Pratt Foundation
- National Institutes of Health (DP2TR002776, / NIDDK R01, / NCI R01, 5r01eb000246-20, CA016520)
- National Cancer Institute (CA016520, R01CA241661, R37CA244911, P30CA016520)
- National Institute of Allergy and Infectious Diseases (T32AI007632)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK123049)
- National Institute of Biomedical Imaging and Bioengineering (R01EB022025, R01-EB000246)
- National Center for Advancing Translational Sciences
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanoparticles, drug delivery, precision medicine, personalized medicine, nanoparticle design, lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, biological barriers, patient heterogeneity, targeted delivery
- MeSH terms
- Biomedical Engineering, Pharmaceutical Preparations, Humans, Drug Delivery Systems, Nanoparticles, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
